We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+31.33%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.21B
AUM Growth
+$361M
Cap. Flow
-$44.8M
Cap. Flow %
-2.03%
Top 10 Hldgs %
47.06%
Holding
101
New
14
Increased
23
Reduced
22
Closed
13

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$56.1M
2
TSM icon
TSMC
TSM
+$37M
3
GS icon
Goldman Sachs
GS
+$36.8M
4
APO icon
Apollo Global Management
APO
+$30.8M
5
FERG icon
Ferguson
FERG
+$29.7M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$91M
2
AMD icon
Advanced Micro Devices
AMD
+$42.8M
3
WYNN icon
Wynn Resorts
WYNN
+$42.5M
4
NVDA icon
NVIDIA
NVDA
+$38.5M
5
AMZN icon
Amazon
AMZN
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 67.65%
2 Technology 8.34%
3 Consumer Discretionary 5.97%
4 Communication Services 5.67%
5 Industrials 4.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
101
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-786,313
Closed -$91M
1 2 3 4
5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Suvretta Capital Management held 101 positions worth $2.21B, up 20% from $1.85B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Suvretta Capital Management's Q4 2023 filing shows 14 new, 23 increased, 22 reduced and 13 closed positions. Its largest new stake was TSMC: 388,232 shares worth $40.4M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $91M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Suvretta Capital Management's largest Q4 2023 buy was TSMC: 388,232 shares worth $40.4M.
  • Suvretta Capital Management added most to Ultragenyx Pharmaceutical in Q4 2023, an estimated $56.1M increase.
  • Suvretta Capital Management's biggest Q4 2023 reduction was Advanced Micro Devices, cutting an estimated $42.8M.
  • Suvretta Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $91M.
  • Suvretta Capital Management's ten largest holdings make up 47% of its $2.21B portfolio in Q4 2023.
  • Suvretta Capital Management opened 14 new positions and closed 13 in Q4 2023.
  • Suvretta Capital Management's portfolio value rose 20% quarter-over-quarter to $2.21B.

Based on Suvretta Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.